Transform Pharmaceuticals, Inc.

Amgen Inc.

Biogen Ma Inc.

University of South Florida

Cephalon, Inc.

Mcneil-ppc, Inc.

Cytokinetics, Inc.

University of Michigan

Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Flextronics Global Services Canada Inc. Services Globaux Flextronics Canada Inc.

Peterson, Matthew

Matthew Lynn Peterson

Julius F Remenar

Magali Bourghol Hickey

Mark Oliveira

Orn Almarsson

Joseph P Lyssikatos

Bin Ma

Brian T Hopkins

Isaac E Marx

Örn Almarsson

Mark Tawa

Robin Prince

Fengmei Zheng

Daniel B Patience

Michael John Zaworotko

Matthew Bio

Michael MacPhee

Jules Remenar

Bradley Paul Morgan

Michele Potashman

David Bauer

Roman Shimanovich

Katrina Woodin Copeland

Sherry Morissette

&Ouml;rn Almarsson

Tanise Shattock

Melanie Cooke

Helming Tan

Hongming Chen

Sheng Cui

Ron C Kelly

Sebastien Caille

Javier Gonzalez-Zugasti

Henry Morrison

Mary Chaves

Nathan R Kane

Kyle Quasdorf

Bin Peter Quan

Hector Guzman

Brian Moulton

David Morgans

Nair Rodriguez-Hornedo

Evelyn Yanez

Lingyun Xiao

David Pearson

Kevin Lu

Jennifer McMahon

Tohru Fukuyama

Öm Almarssoo

Jaclyn Raeburn

Ailsa Golightly

Alex Eberlin

Alexander Oblezov

Oern Almarsson

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Inhibiting agents for bruton's tyrosine kinase

Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

Salts and crystal forms of omecamtiv mecarbil

Inhibiting agents for Bruton's tyrosine kinase

Provided herein is a novel process for the preparation of an amino-pyrimidine and salts thereof. Also provided herein are novel intermediates used in this process and their preparation.

Process for the preparation of an amino-pyrimidine and intermediates thereof

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Polymorphic forms and co-crystals of a c-Met inhibitor

The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.

Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof

Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.

Modafinil compositions

Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.

Pharmaceutical forms, and methods of making and using the same

Hydrated celecoxib sodium salt forms and processes to prepare hydrated celecoxib sodium salt forms are disclosed. The celecoxib sodium salt forms are particularly useful and suitable for pharmaceutical applications.

Hydrated sodium salt form of celecoxib

The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

Pharmaceutical compositions with improved dissolution

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Pharmaceutical co-crystal compositions

Growing community of inventors

Framingham, MA, United States of America

Matthew Lynn Peterson